Pyrintegrin|cas:1228445-38-2|西域试剂

Pyrintegrin,97.03%

产品编号：Bellancom-13306| CAS NO：1228445-38-2| 分子式：C₂₃H₂₅N₅O₃S| 分子量：451.54

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-13306	￥1800.00	杭州北京（现货）
Bellancom-13306	￥2650.00	杭州北京（现货）
Bellancom-13306	￥8500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Pyrintegrin

产品介绍

Pyrintegrin是一种 β1 整合素 (β1-integrin) 激动剂，也是一种 2,4-二取代的嘧啶，可促进胚胎干细胞存活。Pyrintegrin 能增强细胞-细胞外基质 (ECM) 粘附介导的整联蛋白信号传导。Pyrintegrin 可用作足细胞保护剂，并具有强大的成脂作用。

生物活性

Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival. Pyrintegrin enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling. Pyrintegrin can be used as a podocyte-protective agent and has robustly adipogenic.

体外研究

Pyrintegrin (0-10 µM; 1 hour; hASCs) treatment inhibits BMP4-mediated phosphorylation of BMP responsive SMAD1/5 in a dose-dependent manner (IC₅₀ of 1.14 μM).
In vitro, Pyrintegrin stimulats human adipose stem/progenitor cells (hASCs) to differentiate into lipid-laden adipocytes by upregulating peroxisome proliferator-activated receptor (PPARγ) and CCAAT/enhancer-binding protein-α (C/EBPα), with differentiated cells increasingly secreting adiponectin, leptin, glycerol and total triglycerides. Pyrintegrin attenuates Runx2 and Osx via BMP-mediated SMAD1/5 phosphorylation.
Treatment with Pyrintegrin prevents damage-induced decreases in F-actin stress fibers, focal adhesions, and active β1-integrin levels in cultured cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	Human adipose stem/progenitor cells (hASCs)
Concentration:	0 µM, 0.2 µM, 0.5 µM, 1 µM, 2 µM, 5 µM, 10 µM
Incubation Time:	1 hour
Result:	Inhibited BMP4-mediated phosphorylation of BMP responsive SMAD1/5 in a dose-dependent manner.

体内研究
(In Vivo)

Pyrintegrin (10 mg/kg; intraperitoneal injection; once; C57BL/6J mice) treatment protects mice from LPS-induced podocyte foot process effacement and proteinuria. Analysis of the murine glomeruli shows that LPS administration reduces the levels of active β1 integrin in the podocytes, which is prevented by cotreatment with Pyrintegrin.
In rats, Pyrintegrin reduces peak proteinuria caused by puromycin aminonucleoside-induced nephropathy.
Pyrintegrin induces postnatal adipose tissue formation in vivo of transplanted adipose stem/progenitor cells (ASCs) and recruited endogenous cells. In vivo, Pyrintegrin-treated human adipose stem/progenitor cells (ASCs) in 3D-bioprinted scaffolds, when transplanted in the dorsum of athymic mice, yielded ectopically formed adipose tissue that expressed human PPARγ. Remarkably, Pyrintegrin-adsorbed collagen gel implanted in the inguinal fat pad promoted adipogenesis formed by host endogenous cells, suggesting its ability to induce in situ adipogenesis without the need for cell transplantation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female wild type C57BL/6J mice (10-week-old) injected with LPS
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; once
Result:	Provided a significant protection for these animals from LPS-induced proteinuria and foot processe (FP) effacement.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female wild type C57BL/6J mice (10-week-old) injected with LPS
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; once
Result:	Provided a significant protection for these animals from LPS-induced proteinuria and foot processe (FP) effacement.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female wild type C57BL/6J mice (10-week-old) injected with LPS
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; once
Result:	Provided a significant protection for these animals from LPS-induced proteinuria and foot processe (FP) effacement.

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (553.66 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2146 mL	11.0732 mL	22.1464 mL
5 mM	0.4429 mL	2.2146 mL	4.4293 mL
10 mM	0.2215 mL	1.1073 mL	2.2146 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (4.61 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.61 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.61 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.61 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。